Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Sorafenib

Patient with advanced stage HCC receiving sorafenib

It was calculated by dividing the neutrophil count by the lymphocyte count.

The neutrophil-to- lymphocyte ratio

It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL

Prognostic nutrition index

Mona Abdelrahmam, MD

Amr Zagloul, MD

Ahmed othman, MD

Rafat Abd El Aal, MD

Evaluating the nutrition status of patients with advanced HCC who received sorafenib.

Using the pretreatment nutrition status and quality of life as predictors to sorafenib response

This a cross sectional study will be conducted on 100 HCC treated with sorafenib Data were gathered from medical records, including

age sex body weight and height (BMI) pre-therapy laboratory counts of white cells, neutrophils, lymphocytes, monocyte, hemoglobin and platelets; bilirubin, albumin and globulin concentration, AST, ALT, AFP, PT and CONC

Barcelona Clinic Liver Cancer Stage (BCLC) of all patients

The neutrophil-to- lymphocyte ratio (NLR) was calculated by dividing the neutrophil count by the lymphocyte count.

The platelet- to-lymphocyte ratio (PLR) was calculated by dividing the platelet count by the lymphocyte count.

Weight loss difference after treatment Portal hypertension was defined as presence of either collaterals on radiological examination, esophageal varices by upper gastrointestinal endoscopy and/or thrombocytopenia.

Quality of life assessment. QoL was assessed using FACT Hepatobiliary Symptom Index (FHSI-8) Questionnaire. QoL was assessed at base line and 3-6 months after start of treatment.

Predictors of Sorafenib Response in HCC

Predictors of Sorafenib Response in Patients With Advanced Hepatocellular Carcinoma

Sohag University

Principal investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Predictors of Sorafenib Response in HCC	NCT05967429	Hepatocellular ...	The neutrophil-... Prognostic nutr...	-	Sohag University
Predictors of Sorafenib Response in HCC	NCT05967429	Hepatocellular ...	The neutrophil-... Prognostic nutr...	-	Sohag University

Spots Global Cancer Trial Database for prognostic nutrition index